Sigyn Therapeutics, Inc. (SIGY) shareholders
Close on Oct 19, 2026Market cap $48.16KP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Brio Capital Master Fund Ltd. Joint filing with Brio Capital Management LLC (9.99%) | 160,537 | 9.99% | 13G (passive) amendment | Dec 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of SIGY | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Howard Capital Management Group, LLC | 53,000 | 3.30% | $1.35K | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 1 | 0M | 3.3% | 1 / 0 | 0 / 0 | 0M | 0M |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Joseph Segelman Chief Executive Officer, Director, 10% owner | Jun 23, 2017 | Buy | +8,500 | $0.08 | $680 | 25,021,000 |
| Joseph Segelman Chief Executive Officer, Director, 10% owner | Jun 23, 2017 | Buy | +8,500 | $0.18 | $1.53K | 25,021,000 |
| Joseph Segelman CEO, Director, 10% owner | Mar 29, 2017 | Buy | +2,500 | $0.12 | $300 | 25,012,500 |
| Joseph Segelman CEO, Director, 10% owner | Dec 19, 2016 | Buy | +5,000 | $0.10 | $500 | 25,010,000 |
| Joseph Segelman CEO, Director, 10% owner | Dec 14, 2016 | Buy | +5,000 | $0.10 | $500 | 25,005,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 15, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Sigyn Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 300 shares on Aug 26, 2026 over the last 90 days.
See a number that looks wrong?